Company Description
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer.
The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications.
Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020.
Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Country | United States |
| IPO Date | Jan 3, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. |
Contact Details
Address: 712 Vista Boulevard Waconia, Minnesota United States | |
| Website | https://www.panbela.com |
Stock Details
| Ticker Symbol | PBLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001029125 |
| CUSIP Number | 69833W107 |
| ISIN Number | US69833W4042 |
| Employer ID | 87-0543922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D. | Chief Executive Officer, President & Director |
| Susan Horvath | Vice President of Finance, Chief Financial Officer, Secretary & Treasurer |
| Tammy Groene | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 4 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 424B3 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 424B3 | Filing |